A biotechnology company focused on developing cannabinoid-based prescription medicines derived from cannabis. Its lead product, Epidiolex, received regulatory approvals in the U.S. and Europe for certain rare forms of epilepsy, marking one of the first FDA‑approved plant‑derived cannabinoid therapie...
1 member of Congress has disclosed 1 trade in gW Pharmaceuticals Plc (GWPH), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2020-11-05 | John A. Yarmuth | buy | $1K – $15K |